Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Naples – page 76

1 202 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Naples at a glance
1 202
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 202 trials in Naples

Open in trial search

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Glofitamab, Atezolizumab, and Polatuzumab Vedotin for Adults with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALKYLATING AGENTS
  • Sponsor:Geron Corp.

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Neoplasm malignant

Not recruiting

Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Neoplasm

Not recruiting

Study of BMS-986253 with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

HIV infection

Not recruiting

Study on Budigalimab and ABBV-382 for People with HIV on Stable Antiretroviral Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Naples

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.

  • Idiopathic Pulmonary Fibrosis
  • COPD Management
  • RSV Prevention

Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.

  • Breast Cancer Prevention
  • Gastrointestinal Cancers
  • Advanced Solid Tumors

Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.

03 Chronic Diseases

Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.

  • Kidney Disease Management
  • Heart Failure Prevention
  • Neurological Disorders

Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.